Tagraxofusp for Post-Transplant Maintenance

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
44 patients (estimated)
Sponsors
University of Virginia
Tags
CD123, Maintenance, Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2125
NCT Identifier
NCT05233618

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.